UNIVERSITE PAUL SABATIER TOULOUSE III;INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
发明人:
Elvire Gouze
申请号：
US14759535
公开号：
US10724014B2
申请日:
2014.01.16
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
